News

Stay up to date with the latest developments at Ousia Pharma.

Ousia Pharma Secures Substantial Seed Financing Led by Omega Funds to Advance Groundbreaking Obesity Treatment

Financing will support the development of a dual-incretin-NMDA receptor antagonist conjugate through preclinical and early clinical development for the treatment of obesity

Ousia Pharma’s founding research published in Nature, advancing novel obesity treatment

This publication underscores the potential of peptide-directed targeting of NMDA receptors for weight loss, a technology that Ousia Pharma is pioneering.

See the full announcement or read the full article below.

Nature Article

Ousia Pharma receives DKK 10M in funding from the Bioinnovation Institute

The funding will accelerate Ousia Pharma’s development of peptide-drug-conjugates